Skip to content

To study the effect of neuraminidase inhibitor in patient with hypertension

Efficacy of neuraminidase inhibition in hypertension with left ventricular hypertrophy - nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/07/091956
Enrollment
44
Registered
2025-07-29
Start date
Unknown
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I10- Essential (primary) hypertension

Interventions

Intervention1: Oseltamivir: per oral 75mg once a day for 12 weeks Control Intervention1: placebo: per oral once daily for 12 weeks

Sponsors

Postgraduate Institute of Medical Education and Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 18year of age or older, regardless of gender. Diagnosed with essential hypertension for at least 1 year Have been on stable antihypertensive medication for a minimum of 3 months before screening. Have a diagnosis of LVH confirmed by echocardiography, with LVMI of more than or equal to 115g/m for males and more than equal to 95g/m for females. Provide written informed consent

Exclusion criteria

Exclusion criteria: Women who are pregnant and lactating Patients with valvular heart diseases (MR, AR). Patient with inadequate echocardiographic windows. Suboptimal automated speckle tracking across multiple myocardial segment. Any LV regional wall motion abnormalities. Atrial fibrillation, frequent ectopic, left bundle branch block, paced rhythm, or atrioventricular block. Known secondary causes of HTN. Known chronic kidney disease, retinopathy, or cerebrovascular diseases. Known case of congenital heart disease. Any history of previous cardiac surgery

Design outcomes

Primary

MeasureTime frame
Change in LVGLSTimepoint: At 0, 12, and 24 weeks

Secondary

MeasureTime frame
Changes in left ventricular mass index.Timepoint: 12, and 24 weeks;Changes in fractional shorteningTimepoint: 12 and 24 weeks;Left ventricle posterior wall diameter in systole (LVPWs)Timepoint: 12 and 24 weeks;Left ventricle posterior wall diameter in diastole (LVPWd)Timepoint: 12 and 24 weeks;Interventricular septal thickness systole (IVSTs)Timepoint: 12 and 24 weeks;Interventricular septal thickness diastole (IVSTd)Timepoint: 12 and 24 weeks;incidence of adverse events and serious adverse eventsTimepoint: 12 and 24 weeks

Countries

India

Contacts

Public ContactDr Ashish Kakkar

Postgraduate Institute of Medical Education and Research

drashishkakkar@gmail.com9868051003

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026